ArticleMolecular oncology2024

TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer.

Shohei Yoshida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.